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ABSTRACT 43 
Background: Auditory complications are an adverse event of childhood cancer treatment, especially 44 
common in children treated with platinum chemotherapy or cranial radiation. Variation between 45 
diagnostic childhood cancer groups has rarely been studied, and we do not know if the burden of 46 
auditory complications has changed over the last decades. 47 
 48 
Procedure: Within the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to all survivors 49 
who were diagnosed at age 16 years or less between 1976 and 2005.We compared prevalence of self-50 
reported hearing loss and tinnitus between all diagnostic childhood cancer groups and siblings, used 51 
multivariable logistic regression to analyze the effect of treatment-related factors on hearing loss, and 52 
compared the cumulative incidence of hearing loss between different periods of cancer diagnosis. 53 
 54 
Results: Prevalence of self-reported hearing loss was higher in survivors (10%) than in siblings (3%, P 55 
< 0.001), and highest in survivors of central nervous system tumors (25%). Significant risk factors were 56 
treatment with platinum compounds (carboplatin: odds ratio [OR] 2.4; cisplatin: OR 9.4), cranial 57 
radiation (>29 Gy: OR >1.7), or brain surgery (OR 2.2). Children diagnosed in 1986–1995, when 58 
platinum compounds came into widespread use, had a significantly higher cumulative incidence of 59 
hearing loss than those diagnosed in 1976–1985. In the most recent period, 1996–2005, the risk 60 
decreased again, both for patients treated with platinum compounds and with cranial radiation. 61 
 62 
Conclusions: Our data show that the burden of hearing loss has stabilized in recently treated survivors, 63 
suggesting that survivors have benefited from new treatment regimens that use less ototoxic radiation 64 
and more carefully dosed platinum compounds. 65 
  66 
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INTRODUCTION 67 
Ototoxicity, leading to auditory complications like hearing loss or tinnitus, is an adverse event of 68 
childhood cancer treatment, especially common in children treated with platinum chemotherapy or 69 
cranial radiation.1,2 Since its introduction in the 1980s, platinum chemotherapy has been widely used 70 
to treat many kinds of childhood cancer. Platinum compounds can damage the hair cells, the spiral 71 
ganglion neurons, and the stria vascularis in the cochlear duct of the inner ear, and may cause 72 
sensorineural hearing loss or tinnitus in both ears.3–5 Radiation can damage any of the auditory 73 
structures, causing sensorineural, conductive or mixed hearing loss or tinnitus.6,7 The treatment can 74 
affect one or both ears, depending on the area radiated. Auditory complications cause functional 75 
limitations, affect speech development, and impair neurocognitive functioning, educational 76 
performance, and quality of life.8–1 77 
A large U.S. study found an increased risk of auditory complications in a diverse cohort of survivors, 78 
but included only survivors from early diagnosis years (1970–1986).12 Since 1986 ototoxicity from 79 
platinum chemotherapy may have increased as cisplatin came into common use. Later, cisplatin has 80 
been increasingly replaced by the less ototoxic carboplatin, and radiation techniques have improved 81 
and deliver lower radiation doses to the cochlea.13,14 It remains unclear if and how more current 82 
treatment regimens have shifted the burden of long-term auditory complications in survivors of all 83 
diagnostic groups. 84 
Recent estimates of prevalence and incidence of auditory complications vary widely,1 and studies are 85 
hard to compare. Studies on long-term outcomes have tended to focus on selected diagnostic groups, 86 
including brain tumor,15,16 neuroblastoma,8 hepatoblastoma,17 or nasopharyngeal carcinoma,18 or 87 
included a selected treatment group.19 The overall burden of auditory complications and variations 88 
between diagnostic groups have not been well described. We addressed these open questions by 89 
investigating the prevalence of self-reported hearing loss and tinnitus in survivors of all diagnostic 90 
childhood cancer groups, among survivors diagnosed between 1976 and 2005, and compared those 91 
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results to that of siblings. We also assessed the effects of cancer treatment on hearing loss, and if the 92 
incidence of hearing loss has changed over time. 93 
 94 
METHODS 95 
The Swiss Childhood Cancer Survivor Study 96 
The Swiss Childhood Cancer Survivor Study (SCCSS) is a population based, long-term follow-up study 97 
of all patients registered in the Swiss Childhood Cancer Registry (SCCR), who were diagnosed 1976–98 
2005 at age 16 years or less, and who have survived 5 years or more after initial diagnosis of cancer.20 99 
The SCCR is a population-based registry and includes all children and adolescents in Switzerland who 100 
were diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid 101 
tumors, or Langerhans cell histiocytosis before they turned 21.21 102 
From 2007 to 2013, we traced addresses and sent a questionnaire to all survivors.Nonresponderswere 103 
mailed a second copy of the questionnaire 4–6 weeks after the first. If they again did not respond, we 104 
contacted them by phone. We asked survivors for consent to contact their siblings, who made up the 105 
comparison group. If survivors agreed, we sent the same questionnaire to siblings, minus the cancer 106 
related questions. Siblings who did not respond to the first questionnaire received a second copy 4–6 107 
weeks later, but we did not contact them by phone. Details of the study design have been published 108 
elsewhere.20 109 
The Ethics Committee of Canton Bern granted ethical approval to the SCCR and SCCSS. 110 
 111 
Explanatory variables and outcomes 112 
Explanatory variables 113 
We obtained sociodemographic, cancer-, and treatment-related information from the SCCR, which 114 
includes detailed medical information on the tumor and therapy. Missing treatment information was 115 
complemented by data extracted from hospital records. We extracted the following variables from 116 
the SCCR: sex, cancer diagnosis, year and age of cancer diagnosis, age at survey, chemotherapy 117 
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(yes/no), clinical study participation (yes/no), treatment protocol, radiotherapy (yes/no, area, dose), 118 
surgery (yes/no, area, type), and bone marrow transplant (BMT) (yes/no). Cancer diagnosis was 119 
classified according to the International Classification of Childhood Cancer, third edition (ICCC-3).22 120 
We determined whether patients were treated with cisplatin and carboplatin (yes/no) from SCCR data 121 
on clinical study participation and treatment protocols. We summarized radiation doses to the head 122 
and categorized cranial radiation into four categories: no cranial radiation, 1–29 Gy, 30–49 Gy, and 50 123 
Gy or higher. We also collected information on brain surgery (yes/no) and cerebrospinal fluid-shunt 124 
implant (CSF-shunt) (yes/no). To analyze cumulative incidence of hearing loss, we classified the 125 
survivors into four treatment group categories: platinum compounds only, cranial radiation only, 126 
cranial radiation and platinum compounds, and neither of the two treatments. We divided cancer 127 
diagnoses into the following periods: 1976–1985, 1986–1995, and 1996–2005.We divided age at 128 
survey into four categories: 5–15 years, 16–20 years, 21–40 years, and 41–60 years. 129 
 130 
Auditory outcomes 131 
The SCCSSquestionnaire asked survivors and siblings about their auditory health. Participants were 132 
asked if a doctor had told them they had auditory complications (Supplementary Fig. S3) and then 133 
asked to describe the severity and laterality (unilateral/bilateral) of the auditory complication. We 134 
created a binary variable (yes/no) for hearing loss and tinnitus; missing information on auditory 135 
complications was coded as no (hearing loss, 3% in survivors and siblings; tinnitus, 2% in survivors and 136 
1% in siblings).We categorized severity of hearing loss as mild hearing loss, moderate hearing loss, or 137 
deafness.We asked responders who had auditory complications and were older than 15 years at the 138 
time of survey (n = 1,606) for the year of first occurrence of hearing loss. Survivors less than or 15 139 
years old were not included in our analysis of cumulative incidence of hearing loss. 140 
  141 
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Statistical analysis 142 
First, we used chi-square tests to compare prevalence of self-reported hearing loss and tinnitus in 143 
survivors and siblings, and described laterality and severity of hearing loss. We stratified survivors by 144 
diagnostic group and compared prevalence of hearing loss in survivors and siblings. 145 
Second, we performed uni- and multivariable logistic regressions only on survivor data to identify the 146 
effect of cancer-related treatment (use of platinum compounds, cranial radiation, brain surgery, CSF-147 
shunt, and BMT) on hearing loss after cancer diagnosis. We included all treatment-related variables 148 
and adjusted for sex and age at cancer diagnosis in the multivariable regression model according to 149 
the literature.9,23 We computed likelihood ratio tests to calculate global P values. 150 
Third, we used the Kaplan–Meier method to estimate cumulative incidence curves and calculated 151 
cumulative incidence for hearing loss 15 years after cancer diagnosis, stratified by treatment group. 152 
We assessed time trends in cumulative incidence of hearing loss after cancer diagnosis, based on the 153 
period in which the survivor was diagnosed. We estimated incidence curves and hazard ratios (HRs) 154 
for survivors overall and separately for each treatment group and stratified by period of cancer 155 
diagnosis. We used inverse probability weights to adjust the incidence curves for diagnostic groups24 156 
and log-rank tests to test for equivalence of incidence curves. 157 
To increase comparability of survivors and siblings with respect to sex and age at survey, we 158 
standardized the siblings to the survivors by the above-mentioned characteristics (our method is 159 
described in previous publications).25 We imputed age at time of occurrence of hearing loss if a 160 
survivor reported hearing loss but not the year of first occurrence (n = 43).We used observed values 161 
(sex, age at cancer diagnosis, cancer diagnosis, cranial radiotherapy, platinum chemotherapy) in the 162 
imputation model to generate the missing age.26 163 
We used the software package Stata (Version 13, Stata Corporation, Austin, Texas) for all analyses, 164 
and the missforest package for R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria) for 165 
multiple imputation. 166 
 167 
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RESULTS 168 
Characteristics of study population 169 
We contacted 2,884 survivors and 1,526 siblings (Supplementary Fig. S1). Questionnaires were 170 
returned by 2,061 survivors (response rate 71%) and 864 siblings (response rate 57%). 171 
Of the participating survivors, 54% were male; median (interquartile [IQR]) age at survey was 21 years 172 
(6–46) (Table 1). The most common diagnosis among survivors was leukemia (36%), followed by 173 
lymphoma (16%) and CNS tumor (14%). Median (IQR) age at cancer diagnosis was 5 years (0–15); 174 
median (IQR) time since cancer diagnosis was 15 years (5–38). Of survivors who had received 175 
chemotherapy, 6% had been treated with carboplatin, 7% with cisplatin, and 4% with both.Of those 176 
who received radiation, 54% had received cranial radiation. Of those who had had surgery, 25% had 177 
brain surgery and 7% had a CSF-shunt. Five percent of survivors had received a BMT. Responders were 178 
older at survey (P < 0.001), more often female (P < 0.001), more often diagnosed with leukemia or 179 
renal tumor (P = 0.007), and had surgery less often than nonresponders (P = 0.039) (Table 1). 180 
 181 
Prevalence of hearing loss and tinnitus in survivors and siblings 182 
Survivors reported hearing loss more often than siblings did (10 vs. 3%; P < 0.001) (Fig. 1). Hearing loss 183 
was usually mild (7% in survivors vs. 3% in siblings) and rarely moderate (2% in survivors vs. 0% in 184 
siblings) or severe (1% in survivors vs. 0.2% in siblings; P < 0.001) (Table 2). Both unilateral (3% in 185 
survivors vs. 0.9% in siblings) and bilateral (4% in survivors vs. 1% in siblings) hearing loss were more 186 
frequent in survivors than in siblings (P < 0.001). The diagnostic groups differed in prevalence of 187 
hearing loss (Fig. 1). Survivors with a high prevalence of hearing loss were those with CNS tumor (25%), 188 
neuroblastoma (23%), hepatic tumor (21%), bone tumor (16%), soft tissue sarcoma (16%), and germ 189 
cell tumor (20%; all P < 0.001 compared with siblings). Other diagnostic groups had prevalence of 190 
hearing loss comparable to siblings. Prevalence of tinnitus did not differ between survivors and siblings 191 
(4 vs. 5%; P = 0.574). Prevalence of tinnitus was similar in all diagnostic groups and siblings. Survivors 192 
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of CNS tumors showed a non-significant trend toward a slightly increased tinnitus prevalence (P = 193 
0.09; data not shown). 194 
 195 
Treatment-related risk factors for hearing loss after cancer diagnosis 196 
In the univariable regression, survivors treated with carboplatin (odds ratio [OR] 3.5), cisplatin (OR 197 
11.0), or both (OR 12.7) more often developed hearing loss after cancer diagnosis than those who 198 
were not exposed to platinum compounds (P < 0.001) (Table 3). Survivors who had received moderate 199 
or high doses of cranial radiation were more likely to report hearing loss after cancer diagnosis (30–200 
49 Gy: OR 2.7; ≥50 Gy: OR 5.5) than those who had not been cranially irradiated (P < 0.001). Survivors 201 
who had had brain surgery (OR 4.1, P < 0.001), CSF-shunt (OR 3.6, P < 0.001), or BMT (OR 2.3, P = 202 
0.005) were also more likely to develop hearing loss. 203 
In the multivariable regression, survivors with the following treatments were more likely to develop 204 
hearing loss: platinum compounds (carboplatin: OR 2.4; cisplatin: OR 9.4; both combined: OR 8.6; P < 205 
0.001), cranial radiation doses higher than 29 Gy (30–49 Gy: OR 1.7; ≥50 Gy:OR 2.1; P = 0.016), brain 206 
surgery (OR 2.2; P = 0.001), and BMT (OR 2.1; P = 0.023) (Table 3 and Supplementary Fig. S2). 207 
 208 
Cumulative incidence and onset of hearing loss by treatment group 209 
Cumulative incidence of hearing loss 15 years after cancer diagnosis differed between treatment 210 
groups. Survivors treated with both platinum compounds and cranial radiation had the highest 211 
cumulative incidence (63%; 95% confidence interval [CI] 40–98%), followed by those treated with only 212 
platinum compounds (30%; 95% CI 21–42%), only cranial radiation (9%; 95% CI 6–13%), and those who 213 
had had neither of these therapies (5%; 95% CI 4–7%; overall P < 0.001) (Fig. 2). In groups treated with 214 
platinum compounds, cumulative incidence began to increase in the first year after cancer diagnosis. 215 
Survivors treated only with platinum compounds developed hearing loss no later than 7 years after 216 
diagnosis, but in survivors with cranial radiation or both, cranial radiation and platinum compounds, 217 
cumulative incidence continued to increase until 17 years after diagnosis. 218 
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Cumulative incidence of hearing loss by period of cancer diagnosis 219 
Cumulative incidence differed between periods of cancer diagnosis (Fig. 3). We first looked at all 220 
survivors together (panel A). The risk of hearing loss was low for survivors diagnosed 1976–1985, 221 
increased in 1986–1995 with widespread use of platinum compounds in Switzerland, and decreased 222 
again in 1996–2005. Cumulative incidence of hearing loss 15 years after diagnosis was 4% in those 223 
diagnosed in 1976–1985, 12% in those diagnosed in 1986–1995, and 9% in those diagnosed 1996–224 
2005. Accordingly, HRs were 0.41 (95% CI 0.22–0.75) in 1976–1985 and 0.79 (95% CI 0.48–1.30; P = 225 
0.017) in 1996–2005 compared with that in 1986–1995 (HR=1.00, Reference). Second, we looked at 226 
survivors treated with cranial radiation only (panel B). There, cumulative incidence after 15 years was 227 
6% for those diagnosed 1976–1985, increased to 13% for those diagnosed in the second period, and 228 
was lowest (2%) in those diagnosed most recently (1996–2005). Corresponding HRs were 0.45 (95% 229 
CI 0.19–1.07) in 1976–1985 and 0.32 (95% CI 0.07–1.49; P = 0.089) in 1996–2005, compared with that 230 
in 1986–1995. For survivors treated with platinum compounds only (panel C), cumulative incidence 231 
after 15 years was 42% for those diagnosed 1986–1995 and 12% for those diagnosed 1996–2005, with 232 
an HR of 0.27 (95% CI 0.08–0.86; P = 0.027). Finally, we looked at survivors treated with both cranial 233 
radiation and platinum compounds (panel D). In this group, cumulative incidence was 62% for those 234 
diagnosed in 1986–1995 and 39% for those diagnosed in 1996–2005, with a corresponding HR of 0.56 235 
(95% CI 0.23–1.40; P = 0.219). 236 
 237 
DISCUSSION 238 
This comprehensive national survey of hearing loss after childhood cancer found that prevalence of 239 
self-reported hearing loss was significantly higher in childhood cancer survivors than in siblings and 240 
varied between diagnostic groups, with the highest prevalence in survivors of CNS tumors. Incidence 241 
of hearing loss increased significantly after platinum compounds were introduced in the 1980s, but 242 
tended to decrease again in 1996–2005. Prevalence of tinnitus was similar in survivors and siblings. 243 
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We found a high prevalence of hearing loss (10%) among childhood cancer survivors. The U.S. 244 
Childhood Cancer Survivor Study found lower prevalence of self-reported hearing loss (5%) among 245 
survivors of childhood cancer than we did.12 The discrepancy between the two studies may result from 246 
differences in study period and length of observation: The U.S. study did not include survivors 247 
diagnosed after 1986, when platinum compounds came into common use, while we included all 248 
survivors diagnosed up to 2005. Also, the U.S. study assessed prevalence of hearing loss up to 5 years 249 
after diagnosis only, while our mean follow-up time was 15 years. We have shown that cumulative 250 
incidence continues to increase well beyond 5 years from diagnosis particularly for those treated with 251 
cranial radiation. 252 
When we looked at single diagnostic groups, we found that every fourth survivor of CNS tumor or 253 
neuroblastoma reported hearing loss, which is similar to the findings of Christopherson et al.16 in 254 
survivors with CNS tumors (21%) and Gurney et al.8 in survivors of neuroblastoma (31%). 255 
Prevalence of tinnitus was relatively low in our study, in both survivors (4%) and siblings (5%). The U.S. 256 
study found a higher 5-year prevalence in survivors (6%), and differences to siblings (1%).12  257 
We identified platinum compounds, cranial radiation at doses 30 Gy or higher, brain surgery, and BMT 258 
as risk factors for hearing loss. A large body of literature shows the effect of cumulative dose of 259 
platinum compounds on hearing loss.1 Several studies have reported a dose-dependent relationship 260 
between cochlear radiation and hearing loss, with a threshold dose in the range of 35–45 Gy.6,27 261 
Survivors with BMT are at notably increased risk of hearing loss,19,28 but BMT has no ototoxic effect 262 
and is a surrogate for accompanying pre-treatments that include total body irradiation or 263 
myeloablative chemotherapy with high-dose platinum compounds. We found high prevalence of 264 
hearing loss in survivors who had had brain surgery. Brain surgery may lead to auditory complications 265 
when the tumor is located near auditory structures.27,29 We found no association between hearing 266 
loss and CSF-shunt, even though two U.S. studies in children with brain tumors found that rapid 267 
changes in intracranial pressure from hydrocephalus itself or from subsequent shunting affect 268 
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cochlear physiology and can cause hearing loss.27,30 Our study might have underestimated the effect 269 
of CSF shunt, since we had no detailed information on changes in intracranial pressure. 270 
We found the highest cumulative incidence of hearing loss 15 years post-diagnosis in survivors who 271 
had been treated with both platinum compounds and cranial radiation (63%). A U.S. study by Knight 272 
et al.9 found that 80% of patients with medulloblastoma and osteosarcoma, who are often treated 273 
with both cranial radiation or platinum compounds developed hearing loss within 200 days after 274 
diagnosis. When we looked at time intervals between diagnosis and onset of hearing loss, we saw that 275 
auditory complications that followed treatment with platinum compounds always appeared within 7 276 
years of diagnosis. Onset of auditory complications after radiotherapy could occur much later (up to 277 
17 years after diagnosis). Two U.S. studies reported similar time intervals between platinum 278 
administration and detection of hearing loss: 6–82 months in Qaddoumi et al.31 and 12–98 months in 279 
Kolinsky et al.32 The U.S. childhood cancer survivor study reported that survivors who had had cranial 280 
radiation developed hearing loss as late as 15 years after diagnosis.12 We found no other study that 281 
compared cumulative incidence curves between different periods of cancer diagnosis because 282 
previous studies had investigated shorter time periods after cancer diagnosis (e.g., 1970–1986,12,15 283 
1974–1998,19 1995–200823). 284 
In our study, the incidence of hearing loss increased with the widespread introduction of platinum 285 
compounds from 1985 onward, but tended to decrease again for patients diagnosed in the last period, 286 
1996–2005. The decrease in hearing loss after 1995 could be explained by more recent clinical 287 
protocols, which recommend to replace cisplatin with the less toxic carboplatin at the first sign of 288 
auditory complications.33,34 The incidence of hearing loss in survivors who had received only cranial 289 
radiation also tended to decrease after 1996, perhaps because modern protocols use new radiation 290 
techniques like three-dimensional conformal or intensity-modulated radiation therapy.13,14,35 The 291 
decrease in incidence of hearing loss after 1996 could also be caused by the shorter follow-up time 292 
between diagnosis and questionnaire survey in the last period, as it is well known that hearing loss 293 
after cranial radiation may begin many years after treatment. We are currently contacting survivors 294 
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with a second follow-up questionnaire. These data will then allow further investigation of this 295 
potential bias. The consistent results for survivors treated with both cranial radiation and platinum 296 
compounds might be explained by changes in treatment regimens for CNS tumor patients, who made 297 
up a large proportion of our participants. Until the end of the 1980s, these patients had been treated 298 
with radiotherapy instead of chemotherapy. When platinum compounds became available, treatment 299 
regimens changed: CNS tumor patients were prescribed both craniospinal radiation and platinum 300 
compounds.16,36 301 
In the late 1990s, when it became obvious that cranial radiation caused neurocognitive effects, new 302 
protocols reduced radiation doses but intensified platinum chemotherapy.37,38 303 
In summary, most patients diagnosed with CNS tumors, neuroblastomas, hepatic tumors, bone 304 
tumors, soft tissue sarcomas, and germ cell tumors receive ototoxic treatments like platinum 305 
compounds, cranial radiation, or brain surgery. These diagnostic groups are at high risk of hearing loss 306 
and should be closely monitored with audiological tests during, and for many years after cancer 307 
treatment. If auditory complications are detected early, physicians can counsel patients, offer them 308 
hearing aids, and perhaps prevent the progress of hearing loss and secondary effects like impaired 309 
speech development or neurocognitive functioning.10,11,39 310 
Our study has some limitations. First, numbers of survivors with auditory complications were relatively 311 
small in some diagnostic groups and we may have missed some effects because CIs were large. We 312 
used self-reported information on auditory complications, so complications could have been 313 
underreported, especially when hearing was affected only in the high frequencies and did not affect 314 
survivor’s daily life, or when tinnitus after cancer treatment disappeared. However, an Australian 315 
study suggests that self-reports have a reasonable sensitivity (78–100%) for detecting hearing loss 316 
when pure-tone audiometry was used as the gold standard.40 Incidence of hearing loss in the early 317 
period (1976–1985) might be underestimated. Survival rate in this period was lowest, while time lag 318 
between diagnosis and questionnaire mailing was longest. A larger proportion of these survivors may 319 
have died and not been reached by the survey compared with survivors of other decades.Our study 320 
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may also be limited by the fact that we could not narrow the radiation area to the cochlea, though our 321 
approach is supported by earlier studies that report that cochlear doses of radiation are not the 322 
exclusive reason for hearing loss; other head and neck sites are also associatedwith hearing loss.12,41 323 
We could not determine if the effect of platinum compoundswas dose-dependent, as we did not have 324 
exact cumulative doses of platinum compounds. Finally, it remains unclear if other ototoxic drugs (e.g., 325 
aminoglycoside antibiotics or loop diuretics) contribute to the auditory damage, as that information 326 
was not available to us. 327 
Our study was strengthened by its large representative population based sample of childhood cancer 328 
survivors. We followed survivors over a long period of time, covered all diagnostic groups, and also 329 
included survivors who had been diagnosed in different time periods. Our study is the first to 330 
investigate the prevalence of auditory complications among all diagnostic groups of childhood cancer 331 
and to compare incidence between different periods of cancer diagnosis. Few other studies 332 
investigated tinnitus in addition to hearing loss in long-term childhood cancer survivors. 333 
Our findings show that survivors treated with platinum compounds, cranial radiation, or brain surgery 334 
have a higher risk of developing hearing loss. Even though use of platinum compounds with ototoxic 335 
properties has increased in recent years, the burden of hearing loss appears to have stabilized. This 336 
suggests that survivors have benefited from new treatment regimens that use less ototoxic radiation 337 
and more carefully dosed platinum compounds. 338 
 339 
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TABLES 461 
Table 1 462 
Characteristics of childhood cancer survivors and siblings 463 
 464 
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 465 
 466 
ICCC3, International Classification of Childhood Cancer, 3rd edition; N, number; P, P value. 467 
aFor analysis, siblings were standardized on sex and age at study according to the survivors. 468 
bP values calculated from chi-square statistics comparing responding to nonresponding survivors. 469 
cP values calculated from chi-square statistics comparing survivors to siblings. 470 
dOther malignant epithelial neoplasms, malignant melanomas, and other or unspecified malignant 471 
neoplasms. 472 
eEach subject could have had more than one treatment. 473 
fDetailed treatment information not available for nonresponding survivors. 474 
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Table 2  475 
Severity and laterality of self-reported hearing loss in survivors and siblings 476 
a“No” column contains missing. 477 
bPrevalence in siblings is standardized on sex and age at study according to the survivor population. 478 
cP-values calculated from chi-square statistics comparing prevalence in survivors to siblings. 479 
dPercentages are based upon available data. 480 
 481 
 482 
  483 
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Table 3 484 
Effect of treatment-related factors on hearing loss after cancer diagnosis 485 
N, number; P, P values. 486 
aAbsolute numbers of survivors reporting hearing loss after diagnosis. 487 
bRow percentages. 488 
cGlobal P value was calculated with likelihood ratio tests. 489 
dOdds ratios comparing exposed to non exposed childhood cancer survivors, adjusted for use of 490 
platinum compounds, cranial radiation, CSF-shunt, BMT, brain surgery, sex, and age at diagnosis. 491 
eUnivariable analysis restricted to n = 2,059 because of missing values. 492 
fUnivariable analysis restricted to n = 2,036 because of missing values. 493 
 494 
 495 
496 
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FIGURES 497 
Figure 1  498 
Prevalence of self-reported hearing loss and tinnitus in survivors and siblings 499 
CI, confidence interval; CNS, central nervous system. 500 
a(survivors or siblings with hearing loss or tinnitus/total number of persons in this group) 501 
bPrevalence in siblings is standardized on sex and age at study according to survivor population. 502 
P values calculated from chi2-statistics comparing prevalence between survivors of all or of separate 503 
diagnostic groups to siblings. 504 
 505 
  506 
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Figure 2 507 
Cumulative incidence of hearing loss since year of diagnosis, by treatment groups 508 
P, P value. 509 
Analysis is restricted to questionnaires answered by adolescents and adults (n = 1,606). Multiple 510 
imputation was used to impute missing values for year of onset of hearing loss in n = 43. P-value is 511 
calculated with log-rank test. Time of onset of hearing loss was reported in years. 512 
 513 
  514 
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Figure 3 515 
Cumulative incidence of hearing loss after cancer diagnosis based on treatment groups stratified by 516 
period of cancer diagnosis, adjusted for diagnostic group 517 
P, P value. 518 
Analysis is restricted to questionnaires answered by adolescents and adults (n = 1,606). Multiple 519 
imputation was used to impute missing values for year of onset of hearing loss in n = 43. Time of onset 520 
of hearing loss was reported in years. Global P-values are calculated with log-rank tests. 521 
*Since approval for cisplatin was in 1979 and for carboplatin in 1986 in Switzerland, the time period 522 
1976–1985 was not computed. 523 
 524 
 525 
